Mutational spectrum
The syndrome is caused by microdeletions in the 16p13.11-p12.3 genomic region. The 16p13.11 locus is a genomic hotspot particularly rich in low-copy repeats (LCRs), highly homologous DNA sequences that increase the likelihood of copy number mutations through nonallelic homologous recombination. 1 The 16p13.11 region can be subdivided into three single-copy sequence intervals called interval I, II and III, each flanked by LCRs. 2 Typical 16p13.11 microdeletions have very variable size (from 0.8 to 3.3 Mb), and encompass one or more of the three intervals. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Interval II (chr16:15.48-16.32 Mb, GRCh37/hg19) represents the critical region of the genomic variation, being contained in the great majority of the 16p13.11 microdeletions identified so far. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] It encompasses a core set of eight protein-coding genes, including NDE1, the strongest candidate gene for the neurodevelopmental phenotypes associated with the 16p13.11 microdeletions. NDE1 encodes the nuclear distribution protein nudE homolog 1, a centrosomal protein that has a crucial role in the process of mammalian encephalisation and human cerebral cortex growth. 13 Loss of NDE1 in mice causes profound defects in cerebral corticogenesis and neuronal proliferation and migration, and mutations in NDE1 have been associated with extreme microlissencephaly in humans. 14,15 NTAN1 represents another important candidate gene at the 16p13.11 locus, although not included in the critical deleted region. It is located in interval I and encodes the asparagine-specific N-terminal amidase, an enzyme involved in the regulation of the in vivo half life of proteins. Inactivation of the NTAN1 gene in mice has been associated with abnormal neurological features such as altered social behaviour and impaired spatial and non-spatial learning and memory. 16, 17 Sequencing of the NDE1 gene and of the entire 16p13.11 homologous region of the intact chromosome in mentally retarded and epileptic patients carrying the heterozygous microdeletion, did not unmask any relevant recessive-acting mutation, which suggests that haploinsufficiency of one or more dosage-balanced genes included in the region represents one of the principal mechanisms responsible for the pathogenicity of the microdeletion. 4, 8 Mutations published in the literature and mutations submitted without publication are available in a number of resources, including the BBGRE, DECIPHER and ISCA databases, 12, 18, 19 each holding genomic and associated phenotypic data from B5000, B26 000 and B32 000 phenotypically abnormal individuals, or the CHOP CNV and DGV databases, 20, 21 holding CNV data derived from B2000 and B12 000 healthy individuals, respectively. By facilitating interactions between researchers, these international resources provide important tools for genetic research and medical care, aiding the understanding of genotype/ phenotype correlations and the identification of the diseasecausing genes, with consequent improvements in diagnosis, management and therapy for affected individuals.
1.6 Analytical methods FISH, MLPA, array CGH, real-time quantitative PCR (RT-qPCR), SNP-arrays, sequencing. Conventional cytogenetics is usually normal except for rare cases of mosaicism, which are difficult to detect by qPCR studies, but can be identified by array CGH, SNP-arrays or FISH studies.
Analytical validation
MLPA, array CGH, FISH and/or RT-qPCR, depending on the analytical method used.
Estimated frequency of the disease (Incidence at birth ('birth prevalence') or population prevalence):
Prevalence at birth is about 1:14 000 if we only consider carriers affected with a disease, but it is much higher if we consider all the mutation carriers, approximately 1:2300 individuals in the general population. 2, 4, 6, 12 1.9 If applicable, prevalence in the ethnic group of investigated person Not applicable.
Diagnostic setting
Yes No.
Given the highly variable phenotypic manifestations, genetic testing is necessary to make a reliable diagnosis. Analysis of the inheritance pattern of the variations within families is essential to determine the potential need for genetic testing in other relatives, and for assessing the possibility of prenatal diagnosis. 
TEST CHARACTERISTICS
Negative C D Positive predictive value: Negative predictive value:
Analytical sensitivity (Proportion of positive tests if the genotype is present)
Nearly 100% using analytical methods described above.
Analytical specificity (Proportion of negative tests if the genotype is not present)
Clinical sensitivity (Proportion of positive tests if the disease is present)
The clinical sensitivity can be dependent on variable factors such as age or family history. In such cases, a general statement should be given, even if a quantification can only be made case by case.
Variable. The 16p13.11 microdeletions are pleiotropic genomic variants with broad phenotypic manifestations, including neurodevelopmental phenotypes such as autism, mental retardation, epilepsy and learning difficulties and non-CNS phenotypes such as physical dysmorphisms and congenital anomalies. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] This variable phenotypic expressivity represents a challenge for clinical diagnosis because similar clinical features have been associated with a number of other genomic variations (eg, del1q21.1 or del15q11.2), and a characteristic common phenotype for the 16p13.11 microdeletion carriers has not yet been identified. Furthermore, clinical diagnosis can also be hampered by the presence of 'second-hits', additional pathogenic variations in other genomic regions that act in concert with the 16p13.11 microdeletions, and are able to exacerbate or mask some of their phenotypic symptoms. Given these clinical diagnostic limitations, at present, genetic testing is necessary in order to make a secure diagnosis of this syndrome.
Clinical specificity (Proportion of negative tests if the disease is not present)
The clinical specificity can be dependent on variable factors such as age or family history. In such cases, a general statement should be given, even if a quantification can only be made case by case.
Variable. The microdeletion generally shows incomplete penetrance, with some of the carriers being completely unaffected, also within high-risk families. 4, 6, 7, 12 
Positive clinical predictive value (Lifetime risk to develop the disease if the test is positive)
Variable, because of incomplete penetrance of the genomic variation, but higher in males. 12 
Negative clinical predictive value (Probability not to develop the disease if the test is negative)
Assume an increased risk based on family history for a non-affected person. Allelic and locus heterogeneity may need to be considered.
Index case in that family had been tested: Practically 100%. Index case in that family had not been tested: Nearly 100%. Because of the increased risk based on family history, it is advisable to test also an individual not showing clinical symptoms, however, given the incomplete penetrance of the microdeletion, also a carrier subject within an high-risk family can be completely unaffected. brain imaging studies for the detection of anomalies in brain structure; screening for physical dismorphisms and congenital anomalies (eg, cleft lip/palate, heart and kidney defects, genital defects); detection of behavioural problems, speech delay and learning difficulties; screening for hypotonia, feeding difficulties and delayed motor skills; detection of hearing loss and eye problems. Family support through patient organisations is generally available. 
CLINICAL UTILITY

Predictive
IF APPLICABLE, FURTHER CONSEQUENCES OF TESTING
Please assume that the result of a genetic test has no immediate medical consequences. Is there any evidence that a genetic test is nevertheless useful for the patient or his/her relatives? (Please describe). A characteristic common phenotype for the 16p13.11 microdeletion carriers has not yet been identified, consequently, genetic testing is necessary to make a reliable diagnosis of this syndrome. A positive genetic test provides specific information about the possible clinical manifestations and orients clinicians towards targeted screening and intervention. Analysis of the inheritance pattern of the genomic variation has direct consequences for the genetic counselling of relatives and provides indications about the clinical utility of prenatal testing. Although there is no specific cure for this syndrome, detailed analysis of the genomic variations detected by genetic testing may help to identify the specific disease-causing genes in the pathogenic region and to clarify the yet poorly understood disease pathophysiology, thus providing critical means for the design of new treatments. 
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